Watch Tenaya Therapeutics Inc for free: we tell you when fair value or trend changes.

Tenaya Therapeutics Inc (TNYA) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Tenaya Therapeutics Inc stock $0.31, price $0.36, that is 15.0% below the price, quality 40 out of 100. Rating: overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

1 model in detailBear $0.2040 to bull $0.3825 Growth analysisrevenue history, year by year Quality 40/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

Thin data Nov 6, 2026

Tenaya Therapeutics Inc

TNYA · US

Expensive, weak quality

Our calculation puts a fair price 15% below what the stock costs today.

Positive coverage

Quality 40/100

Mixed vs. peers (3/7)

Insiders sold $27,373 (6M)

Fair value $0.3060 · Overvalued

Negative free cash flow

Narrow moat 3/100 · thin data

Thin data

⚠ Dilution

Watch Tenaya Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range $0.3160 – $29.58 · fair‑value band $0.2040 – $0.3825 · the $0.3602 price screens above the $0.3060 fair value. As of Nov 6, 2026.

Follow Tenaya Therapeutics in your weekly email

Every Wednesday you see whether Tenaya Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

Show moreShow less

Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.

The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease.

Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Stock analysis

Tenaya Therapeutics Inc (TNYA) currently trades at $0.3602, while our model-based Fair Value estimate is $0.3060, 15% below the price, so the stock looks overvalued today.

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $0.2040 (bear) to $0.3825 (bull), the price of $0.3602 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Tenaya Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$90.6M in FY2025.

Key figures

Market cap $78.4M Micro · P/S ratio 63.2 · EPS (TTM) $−0.5200 · Return on equity −122% · Return on assets (EBIT) −61.0% (5-year average) · Operating margin −1,883% · Revenue (TTM) $1.3M · Free cash flow −$68.9M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 77% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −15%, TNYA screens richer than that median.

Fair Value models

Bear $0.2040 Fair Value $0.3060 Bull $0.3825

Price $0.3602 · Downside -15.0%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

NCAV (Graham) $0.2400 $0.3600 $0.4500 52

All 1 models by family

Asset-Based

NCAV (Graham) $0.2400 $0.3600 $0.4500 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0

How much profit the company makes from its sales and capital

Quality Growth 75

Are margins and returns getting better?

Cashflow 17

Do the profits arrive as real cash?

Financial strength 75

Debt, balance sheet and risk of trouble

Investment 100

Does it invest with discipline instead of growing at any price?

Low Volatility 0

How calm the share price moves, does not count

Price momentum 0

Price momentum of the last 3 to 12 months, does not count

Near the 52-week high 2

Distance to the 52-week high, does not count

New shares 0

Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors sold shares worth $27,373 and none bought.

SaleWhittemore TingleyChief Medical Officer4× since Nov 17, 2025: 18,582 shares, avg. $0.8000$14,865Aug 17, 2026
SaleFaraz AliChief Executive Officer, Director4× since Nov 17, 2025: 43,610 shares, avg. $0.7368$32,132Aug 17, 2026
SaleTomohiro HigaSVP, Finance3× since Nov 17, 2025: 6,321 shares, avg. $0.8245$5,211May 18, 2026
SaleTCG Opportunity III GP, LLC10% owner4,170,266 shares at $0.5695$2.4MFeb 25, 2026
SaleCOLUMN GROUP III-A, LP10% owner2× since Feb 10, 2026: 5,230,024 shares, avg. $0.6775$3.5MFeb 23, 2026

Plus 2 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss

not computed

TNYA screens overvalued: fair value 15% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Recent news

News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive

Recent news coverage is more positive than average.

Tenaya Therapeutics, Inc. (TNYA) Reports Q3 Loss, Beats Revenue Estimates Yahoo Finance · Nov 4, 2026
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Yahoo Finance · Aug 5, 2026
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire · Jul 15, 2026
Tenaya Therapeutics Names Eric Hyllengren CFO Ahead Of Higa Retirement Nasdaq · Jun 30, 2026

Compare Tenaya Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 557 stocks

Beats the industry median on 3/6 measures

A mixed picture versus its industry peers.

Valuation

Quality Score 40 · Below median

Fair Value upside −15.0% · Above median

Profitability

Return on assets −61.7% · Bottom 25%

Growth and dividend

Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.64× · Cheapest 25%

P/S (12 months) 58.70× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)13 · sector 0

FUTURE (revenue growth)0 · sector 0

PAST (return on equity)0 · sector 0

HEALTH (low debt)0 · sector 97

DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Incyte Corporation INCY	$119.65	$199.23	+67%	vs TNYA
Regeneron Pharmaceuticals, Inc REGN	$904.35	$1,275	+41%	vs TNYA
Genmab A/S GMAB	kr 3,527	kr 3,999	+13%	vs TNYA
Samsung Biologics Co 207940	1,516,000 KRW	1,667,600 KRW	+10%	vs TNYA
WuXi Biologics (Cayman) Inc 2269	HK$47.62	HK$52.38	+10%	vs TNYA
Vertex Pharmaceuticals Incorporated VRTX	$547.09	$596.75	+9%	vs TNYA
argenx SE ARGX	$927.21	$908.40	−2%	vs TNYA
CSL Limited CSL	A$202.04	A$183.04	−9%	vs TNYA
Celltrion, Inc 068270	211,000 KRW	74,945 KRW	−64%	vs TNYA
Royalty Pharma plc RPRX	$67.30	$19.01	−72%	vs TNYA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks Undervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Tenaya Therapeutics Inc: fair value per Fair Value Calculator

<a href="https://www.fairvalue-calculator.com/stock/TNYA?utm_source=embed&amp;utm_medium=badge" target="_blank" rel="nofollow noopener"><img src="https://www.fairvalue-calculator.com/embed/TNYA.US.svg" width="360" height="84" alt="Tenaya Therapeutics Inc: fair value per Fair Value Calculator" style="border:0;max-width:100%" loading="lazy"></a>

Cite: Fair Value Calculator (2026). "Tenaya Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/TNYA

Frequently asked questions

Is Tenaya Therapeutics Inc (TNYA) overvalued or undervalued?

As of Nov 6, 2026, our model estimates a fair value of $0.3060 versus a price of $0.3602, about 15% lower (overvalued).

What is the fair value of TNYA?

Our model-based fair value for Tenaya Therapeutics Inc is $0.3060 (as of Nov 6, 2026), built from audited fundamentals. The current price: $0.3602.

What is the quality score of TNYA?

Tenaya Therapeutics Inc has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Tenaya Therapeutics Inc (TNYA)?

Our model-based price target is the fair value of $0.3060 (as of Nov 6, 2026) from 1 valuation models. Cautious scenario $0.2040, optimistic scenario $0.3825. It is a calculation from audited fundamentals, not an analyst target.

What is the Tenaya Therapeutics Inc stock forecast for 2026?

Our models put fair value at $0.3060, about 15% lower versus a price of $0.3602 (overvalued). Cautious scenario $0.2040, optimistic scenario $0.3825. The calculation is refreshed regularly with new filings.

What is the revenue of Tenaya Therapeutics Inc (TNYA)?

Tenaya Therapeutics Inc reported trailing-twelve-month revenue of about $1.3M (latest available figure, as of Nov 6, 2026).

What is the intrinsic value of Tenaya Therapeutics Inc (TNYA)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tenaya Therapeutics Inc it is $0.3060 per share (as of Nov 6, 2026), against a price of $0.3602. It is the blended result of 1 valuation models in 1 family (Asset-Based).

Is Tenaya Therapeutics Inc stock overvalued or undervalued in 2026?

As of Nov 6, 2026, TNYA trades above its calculated fair value: price $0.3602, fair value $0.3060, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of TNYA?

No. The price is what the market pays today ($0.3602); the fair value is what the company's own numbers justify ($0.3060). For Tenaya Therapeutics Inc the two are $0.0542 per share apart. That gap is exactly why we show both numbers side by side.

How much is Tenaya Therapeutics Inc worth?

The market values Tenaya Therapeutics Inc at about $78.4M (market capitalisation, as of Nov 6, 2026). Per share that is $0.3602; our models calculate a fair value of $0.3060 per share.

What do the bullish and bearish scenarios say about TNYA?

Our models span a range for Tenaya Therapeutics Inc: cautious scenario $0.2040, base $0.3060, optimistic $0.3825 per share (as of Nov 6, 2026, price $0.3602). The range comes from different growth and margin assumptions, not from analyst opinions.

How solid is the balance sheet of Tenaya Therapeutics Inc (TNYA)?

Balance-sheet figures for Tenaya Therapeutics Inc (as of Nov 6, 2026): return on equity −121.9%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.

How far is TNYA from its 52-week high?

Tenaya Therapeutics Inc trades at $0.3602, about 77% below its 52-week high of $1.54 and 14% above the low of $0.3160 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3060 is for.

Which stocks are comparable to Tenaya Therapeutics Inc?

From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Tenaya Therapeutics Inc stock attractive at the current price?

The data as of Nov 6, 2026: price $0.3602, calculated fair value $0.3060 (−15%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of TNYA calculated?

We run Tenaya Therapeutics Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $0.3060 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.3% above its aggregate fair value. Tenaya Therapeutics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Tenaya Therapeutics Inc (TNYA)?

The closing price on Nov 6, 2026 was $0.3602. Our model-based fair value is $0.3060, about 15% lower (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Tenaya Therapeutics Inc right now?

Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($0.2040 to $0.3825) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Tenaya Therapeutics Inc

How large is the market capitalisation of Tenaya Therapeutics Inc (TNYA)?

The market capitalisation of Tenaya Therapeutics Inc is $78.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Tenaya Therapeutics Inc (TNYA)?

The price-to-sales ratio of Tenaya Therapeutics Inc is 63.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Tenaya Therapeutics Inc (TNYA)?

Earnings per share at Tenaya Therapeutics Inc are $−0.5200. Earnings per share over the last twelve months: total profit spread across every single share.

What is the return on equity of Tenaya Therapeutics Inc (TNYA)?

The return on equity (ROE) of Tenaya Therapeutics Inc is −122% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Tenaya Therapeutics Inc (TNYA)?

On an EBIT basis the return on assets of Tenaya Therapeutics Inc is −61.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Tenaya Therapeutics Inc (TNYA)?

The operating margin of Tenaya Therapeutics Inc is −1,883% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How much free cash flow does Tenaya Therapeutics Inc (TNYA) generate?

The free cash flow of Tenaya Therapeutics Inc is −$68.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

How much net cash does Tenaya Therapeutics Inc (TNYA) hold?

Tenaya Therapeutics Inc holds more cash than debt, $89.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch Tenaya Therapeutics Inc in the live analysis

One click puts Tenaya Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.